ENVB: רווח למניה בשנים עשר החודשים האחרונים Enveric

Enveric Biosciences focuses on pre-commercial research, which leads to full capital depletion in the absence of revenue. The development of psychedelics is independent of economic conditions, relying instead on clinical trial data. The PsyAI platform automates molecule discovery using AI. TTM earnings per share dynamics help filter out speculation, with the value fixed at -16.59.

For Enveric Biosciences (ENVB), a leader in developing evidence-based psychedelic therapies, this indicator serves as a measure of actual capitalization efficiency. The calculation is based on dividing total annual net income by the total number of shares. By analyzing changes in the rolling annual EPS, an investor can see the actual equity return of the business. This metric separates market expectations from financial reality, allowing for an assessment of the value of innovation in the context of profit.